ArticleBritish journal of pharmacology2008
Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways.
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC).EMBO molecular medicine · 2026Article
- Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.International journal of molecular sciences · 2025Review
- Article
- Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-retroviral toxic neuropathy.Pharmacological research · 2023Article
- Cannabinoids pharmacological effects are beyond the palliative effects: CB2 cannabinoid receptor agonist induced cytotoxicity and apoptosis in human colorectal cancer cells (HT-29).Molecular and cellular biochemistry · 2021Article
- Novel Mixed NOP/Opioid Receptor Peptide Agonists.Journal of medicinal chemistry · 2021Article
- Endocannabinoid System in the Airways.Molecules (Basel, Switzerland) · 2019Review
- Indole compounds withMedChemComm · 2019Article
- Article
- Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55.Frontiers in pharmacology · 2018Review
- Role of EP2 and EP4 receptors in airway microvascular leak induced by prostaglandin E2.British journal of pharmacology · 2016Article
- Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.British journal of pharmacology · 2014Article
- Theophylline inhibits the cough reflex through a novel mechanism of action.The Journal of allergy and clinical immunology · 2014Article
- Tiotropium modulates transient receptor potential V1 (TRPV1) in airway sensory nerves: A beneficial off-target effect?The Journal of allergy and clinical immunology · 2014Article
- Article
- Antitussive drugs--past, present, and future.Pharmacological reviews · 2014Review
- Article
- Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons.Molecular pain · 2010Article
- CB2: a cannabinoid receptor with an identity crisis.British journal of pharmacology · 2010Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
background and purposeSensory nerves regulate central and local reflexes such as airway plasma protein leakage, bronchoconstriction and cough. Sensory nerve activity may be enhanced during inflammation such that these protective effects become exacerbated and deleterious. Cannabinoids are known to inhibit airway sensory nerve function. However, there is still controversy surrounding which receptor is involved in eliciting these effects. EXPERIMENTAL APPROACH: We have adopted a pharmacological approach, including using a novel, more selective CB(2) receptor agonist, GW 833972A (1000-fold selective CB(2)/CB(1)), and receptor selective antagonists to investigate the inhibitory activity of cannabinoids on sensory nerve activity in vitro and in vivo in guinea-pig models of cough and plasma extravasation. KEY
resultsGW 833972A inhibited capsaicin-induced depolarization of the human and guinea-pig and prostaglandin E(2) (PGE(2)) and hypertonic saline-induced depolarization of the guinea-pig isolated vagus nerve in vitro. GW 833972A also inhibited citric acid-induced cough but not plasma extravasation in the guinea-pig and this effect was blocked by a CB(2) receptor antagonist. CONCLUSIONS AND IMPLICATIONS: This confirms and extends previous studies highlighting the role of CB(2) receptors in the modulation of sensory nerve activity elicited both by the exogenous ligands capsaicin and hypertonic saline but also by endogenous modulators such as PGE(2) and low pH stimuli. These data establish the CB(2) receptor as an interesting target for the treatment of chronic cough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.